EUVIMEDSkopri EUVIMED
Vergleichsstudie

Citrate Versus Citrate–Heparin Anticoagulation in HPC (A): Comparative Effects on Intra‐Apheresis Mobilization of CD34 + Hematopoietic Progenitor Cells

Yandy Marx Castillo-Aleman iD, Carlos Agustin Villegas-Valverde iD, Antonio Alfonso Bencomo-Hernandez iD, Shinnette Lumame iD, Charisma Castelo iD, Jay Mary Rose-Roque iD, Marlene Cato iD, Nameer Al-Saadawi iD, Mohamed Ibrahim Abu-Haleeqa iD, Aseel Suleiman Alsaid iD, Sakher Ahmad Obeidat iD, Mansi Sachdev iD and 5 more

Journal of Clinical Apheresis · 2026-04 · 41 (2)

DOI: 10.1002/jca.70118 ↗

At a glance

Vergleichsstudie in Journal of Clinical Apheresis, published online on 2026-03-27. Written by Yandy Marx Castillo-Aleman and 16 co-authors. Institution: Abu Dhabi Stem Cells Center (ADSCC), Abu Dhabi, UAE. Major MEDLINE topics: Heparin, Anticoagulants, Citric Acid, Blood Component Removal. 22 references.

AstrattSubjectsDettalji biblijografiċiCiteRelated studies

Abstract (original language)

Successful hematopoietic stem cell transplantation relies on the collection of a sufficient number of CD34 + hematopoietic progenitor cells (HPCs). While acid citrate dextrose solution A (ACD‐A) is a common anticoagulant (AC) for HPC apheresis [HPC(A)], recent evidence suggests that concomitant heparin may enhance intra‐apheresis recruitment (IAR) of CD34 + cells and improve collection efficiency. This study aimed to compare citrate‐only and citrate–heparin protocols in routine HPC(A) procedures, with a focus on their effects on IAR and efficiency outcomes. A retrospective analysis was performed on 266 HPC(As) from 193 apheresis donors in autologous and allogeneic settings. Donor demographics, procedural parameters, and collection outcomes were compared between the ACD‐A–only and ACD‐A plus heparin protocols. The study endpoints included apheresis yield (AY/kg), collection efficiencies (CE 1 , CE 2 , and cruCE), recruitment ratio (RR), and performance ratio (PR). Statistical analyses included Mann–Whitney U tests, effect sizes, and partial least squares (PLS) regression. Heparinized procedures demonstrated higher processed total blood volume ratios, lower AC volumes, and superior outcomes across CE 1 (83.8% vs. 72.5%, p = 0.00027), CE 2 (70.8% vs. 64.2%, p = 0.0055), cruCE (77.0% vs. 72.4%, p < 0.0001), RR (2.3 vs. 1.7, p < 0.0001), PR (239.3% vs. 208.2%, p < 0.0001), and AY/kg (6.75 vs. 5.23 × 10 6 CD34 + cells/kg, p = 0.0025). The effect size and PLS analyses confirmed the contribution of heparin as an adjunct AC enhancing multiple apheresis outcomes. In summary, citrate–heparin anticoagulation was found to be a feasible strategy that improved key collection efficiency and IAR metrics during HPC(A).

Subjects

MeSH terms (MEDLINE)

HeparinAnticoagulantsCitric AcidBlood Component RemovalHematopoietic Stem Cell MobilizationHematopoietic Stem CellsHumansAntigens, CD34FemaleRetrospective StudiesMaleAdultMiddle AgedCitratesGlucose

Author keywords

anticoagulantscitratehematopoietic stem cell mobilizationheparinleukapheresis

Substances

HeparinAnticoagulantsCitric AcidAntigens, CD34acid citrate dextroseCitratesGlucose

Authors and institutions

  • Abu Dhabi Stem Cells Center (ADSCC), Abu Dhabi, UAE.
  • Yas Clinic Khalifa City (YCKC) Hospital, Abu Dhabi, UAE.
  • United Arab Emirates University (UAEU), Abu Dhabi, UAE.

ORCID profiles: Yandy Marx Castillo-Aleman, Carlos Agustin Villegas-Valverde, Antonio Alfonso Bencomo-Hernandez, Shinnette Lumame, Charisma Castelo, Jay Mary Rose-Roque, Marlene Cato, Nameer Al-Saadawi, Mohamed Ibrahim Abu-Haleeqa, Aseel Suleiman Alsaid, Sakher Ahmad Obeidat, Mansi Sachdev, Jayakumar David Dennison, Inas El-Najjar, Rene Antonio Rivero-Jimenez, Yendry Ventura-Carmenate, Fatema Mohammed Al-Kaabi

Cite

APA

Castillo-Aleman, Y. M., Villegas-Valverde, C. A., Bencomo-Hernandez, A. A., Lumame, S., Castelo, C., Rose-Roque, J. M., Cato, M., Al-Saadawi, N., Abu-Haleeqa, M. I., Alsaid, A. S., Obeidat, S. A., Sachdev, M., Dennison, J. D., El-Najjar, I., Rivero-Jimenez, R. A., Ventura-Carmenate, Y., & Al-Kaabi, F. M. (2026). Citrate Versus Citrate–Heparin Anticoagulation in HPC (A): Comparative Effects on Intra‐Apheresis Mobilization of CD34 + Hematopoietic Progenitor Cells. Journal of Clinical Apheresis, 41(2). https://doi.org/10.1002/jca.70118

Vancouver

Castillo-Aleman YM, Villegas-Valverde CA, Bencomo-Hernandez AA, Lumame S, Castelo C, Rose-Roque JM, et al. Citrate Versus Citrate–Heparin Anticoagulation in HPC (A): Comparative Effects on Intra‐Apheresis Mobilization of CD34 + Hematopoietic Progenitor Cells. Journal of Clinical Apheresis. 2026;41(2). doi:10.1002/jca.70118

BibTeX
@article{CastilloAleman2026,
  author = {Castillo-Aleman, Yandy Marx and Villegas-Valverde, Carlos Agustin and Bencomo-Hernandez, Antonio Alfonso and Lumame, Shinnette and Castelo, Charisma and Rose-Roque, Jay Mary and Cato, Marlene and Al-Saadawi, Nameer and Abu-Haleeqa, Mohamed Ibrahim and Alsaid, Aseel Suleiman and Obeidat, Sakher Ahmad and Sachdev, Mansi and Dennison, Jayakumar David and El-Najjar, Inas and Rivero-Jimenez, Rene Antonio and Ventura-Carmenate, Yendry and Al-Kaabi, Fatema Mohammed},
  title = {Citrate Versus Citrate–Heparin Anticoagulation in HPC (A): Comparative Effects on Intra‐Apheresis Mobilization of CD34 + Hematopoietic Progenitor Cells},
  journal = {Journal of Clinical Apheresis},
  year = {2026},
  volume = {41},
  number = {2},
  doi = {10.1002/jca.70118}
}
Start for free →